<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04724577</url>
  </required_header>
  <id_info>
    <org_study_id>SPHIC-TR-PCa2019-01</org_study_id>
    <nct_id>NCT04724577</nct_id>
  </id_info>
  <brief_title>12 Fractions Carbon Ion Radiotherapy for Localized Prostate Cancer</brief_title>
  <official_title>Phase I Study on Carbon Ion Radiotherapy in 12 Fractions for Localized Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Proton and Heavy Ion Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Proton and Heavy Ion Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The arm of this study is to explore the optimal dose of 12 fractions of carbon ion&#xD;
      radiotherapy for prostate cancer in our center.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The radiation dose of 51.6GyE in 12 fractions is currently widely used in Japan, and clinical&#xD;
      studies of 51.6GyE/12Fx have also been carried out for SBRT. There are some differences in&#xD;
      equipment and carbon ion treatment planning system used between Japan and our center.&#xD;
      Therefore, we designed this phase I clinical study to explore the optimal dose of 12&#xD;
      fractions of carbon ion radiotherapy for prostate cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>dose escalation study for carbon ion radiotherapy in prostate cancer</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute toxicity</measure>
    <time_frame>3 months after the completion of CIRT</time_frame>
    <description>Treatment related acute toxicity assessed by CTCAE v4.03</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical failure free survival,bFFS</measure>
    <time_frame>From the complation of CIRT,a median of 5 years</time_frame>
    <description>The PSA less than nadir plus 2ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the diagnosis of prostate cancer,a median of 5 years</time_frame>
    <description>The time from diagnosis to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From the complation of CIRT,a median of 5 years</time_frame>
    <description>The time from complation of CIRT to tumor progression or death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Radiotherapy</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Carbon ion treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose escalation study with five dose levels [54GGyE(Gray equivalent)/12Fx,55.2GyE/12Fx,56.4GyE/12Fx,57.6GyE/12Fx and 58.8GyE/12Fx ].</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>carbon ion radiotherapy</intervention_name>
    <description>dose escalation radiotherapy with five levels of dose from 54GyE/12Fx to 58.8GyE/12Fx</description>
    <arm_group_label>Carbon ion treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically confirmed adenocarcinoma of prostate&#xD;
&#xD;
          -  Stage cT1-3N0M0 localized prostate cancer&#xD;
&#xD;
          -  No lymph nodes or distant metastasis&#xD;
&#xD;
          -  Age ≥ 45 and &lt; 85 years of age&#xD;
&#xD;
          -  Karnofsky Performance Score ≥70&#xD;
&#xD;
          -  No previous pelvic radiation therapy (RT)&#xD;
&#xD;
          -  No previous prostatectomy&#xD;
&#xD;
          -  No previous invasive cancer (within 5 years before the prostate cancer diagnosis)&#xD;
&#xD;
          -  Ability to understand character and individual consequences of the clinical trial&#xD;
&#xD;
          -  Willing to sign the written informed consent; Informed consent must be signed before&#xD;
             the enrollment in the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No pathologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          -  Pelvic lymph node metastasis (N1)&#xD;
&#xD;
          -  Distant metastasis (M1)&#xD;
&#xD;
          -  Previous pelvic radiotherapy&#xD;
&#xD;
          -  Previous prostatectomy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male patients with prostate cancer</gender_description>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai Proton and Heavy Ion Center</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping Li</last_name>
      <phone>38296666</phone>
      <email>ping.li@sphic.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Qing Zhang</last_name>
      <phone>38296666</phone>
      <email>qing.zhang@sphic.org.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 23, 2021</study_first_submitted>
  <study_first_submitted_qc>January 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Proton and Heavy Ion Center</investigator_affiliation>
    <investigator_full_name>Ping Li</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>localized prostate cancer</keyword>
  <keyword>carbon ion radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

